Key pharmaceutical company stories.
- UCB: Integrating Schwarz
IMS recently interviewed Dr Melanie Lee, Executive VP, Research & Development at UCB. An excerpt from the transcript follows in which she discusses the major highlights for the company in the last few years and also how the acquisition of Schwarz Pharma has affected UCB's R&D strategy.
- Nycomed: meeting challenges head on
Hakan Bjorklund, CEO of Nycomed, talks to IMS about the transformation of his company following its acquisition of Altana Pharma.
Jan 23, 2008
- Hitting targets at Wyeth
Wyeth's President of R&D Robert Ruffolo explains to IMS why he is optimistic about his company's upcoming products, despite some recent setbacks at the FDA.
Dec 10, 2007
- Pfending off the competition
As generic statins continue to take market share, Pfizer is seeking to defend and grow its revenues from top-seller Lipitor.
Nov 1, 2007
- Almirall goes public and steps out of Spain
Jorge Gallardo, CEO of the largest Spanish pharmaceutical corporation, discusses his company's internationalisation efforts and most important R&D compound.
Nov 1, 2007
- Allergan looks to the future
IMS recently interviewed Allergan CEO David Pyott, who discussed the ophthalmology specialist's potential moves into urology and neurology.
Jun 6, 2007
- Sanofi Pasteur boosts manufacturing capacity to meet increasing demand
Wayne Pisano of sanofi-aventis' vaccines division explains to IMS his views on the potential of the reinvigorated vaccines market.
Apr 29, 2007
- Solvay's strategies for growth
In an exclusive interview with IMS, General Manager of Solvay Pharmaceuticals Werner Cautreels discusses the integration of Fournier and his company's plans for future growth.
Apr 10, 2007
- Lundbeck looks to the US to fuel growth
Claus Braestrup, CEO of Denmark's Lundbeck, tells IMS that his company will maintain its focus on CNS products, but spread its wings geographically and build a presence in the all-important US market.
Mar 1, 2007
- Q&A with the CEO of UCB
Roch Doliveux spoke to IMS recently about UCB’s activities and strategies in various regional markets, including the US, Japan and China.
Dec 5, 2006
